THE REGISTRO ITALIANO TROMBOCITEMIE (RIT): PRELIMINARY ANALYSIS OF THE FIRST 767 ENROLLED PATIENTS
Results
L. Gugliotta and A. Tieghi for the RIT Panel *
Background
RIT Institutions
• Alessandria
• Ancona
•Ascoli Piceno
•Avellino
•Bari
•Bologna
•Bolzano
•Brindisi
•Cagliari
•Campobasso
•Carbonara di Bari
•Castelfranco Veneto
•Catania
•Catanzaro
•Civitanova Marche
•Como
•Cosenza
•Crema
•Cremona
•Firenze
•Firenze Ist.L.da Vinci
•Genova S.Martino
•Genova DIMI
•Genova Ematologia I
•L’Aquila
•La Spezia
•Mantova
•Matera
•Messina Papardo
•Messina Policlinico
•Milano S.Paolo
•Milano Ist. Tumori
•Milano Policlinico
•Milano S. Raffaele
•Milano Ematologia II
•Modena
•Montefiascone
•Monza
•Napoli S.Gennaro
•Napoli S.G.Bosco
•Napoli Federico II
•Nocera Inferiore
•Novara
•Orbassano
•Padova
•Palermo La Maddalena
•Parma
•Pavia Clinica Med.III
•Pavia Ematologia
•Perugia
•Pesaro
•Pescara
•Piacenza
•Pisa
•Pordenone
•Ragusa
•Ravenna
•Reggio Calabria
•Reggio Emilia
•Rionero in Vulture
•Roma S.G.Addolorata
•Roma Osp. San Giacomo
•Roma La Sapienza
•Roma Gemelli
•Roma Tor Vergata
•Roma S.Eugenio
•Roma S.Spirito
• Roma Campus Biomedico
• Roma A.O. Sant’Andrea
•Rozzano
•S.Felice a Cancello
•S.Giovanni Rotondo
•Siena
•Sondalo
•Torino
•TorinoM
•Udine
•Vicenza
78 Centers
AGE at Diagnosis
SEX
PREVIOUS THROMBOSIS
Major
4%
2%
PREVIOUS HEMORRHAGE
1%
Males
40
Females
30
Aims
•To registry ET patients observed in the italian Institutions.
•To validate the diagnosis appropriateness (WHO criteria) by performing
a centralized revision of the bone marrow biopsies
•To promote the acquisition of biological data (clonality, JAK2 mutation, haemostasis)
•To evaluate the compliance to the therapeutical guide lines of the Italian Society of
Haematology
•To monitor the ET patients receiving Interferons alpha or Anagrelide
•To evaluate cases of pregnancy, pediatric age and familiarity
•To create a network for activation of new clinical and biological studies
Methods
767 Patients
767
The RIT, co-ordinated by the Haematology Unit of Reggio Emilia, is a web-based
registry (www.trombocitemie.it) that, besides a public area, comprehends a
database of italian ET patients.
The data, with respect of the privacy rules, are object of validation and analysis by
various RIT Expert Subcommittees.
20
SYMPTOMS
%
S. Rupoli, A.Tassetti , N. Cantore, F. Palmieri, V. Liso, G. Specchia, P.Carluccio, C. Cristofalo, C. Gasbarrino, P.
Ditonno, E. DE Biasi, E. Cacciola, R. Cacciola, R. Centurioni, A. Inzoli, P. Spedini, A. Bosi, A. M. Vannucchi, E.
Antonioli, A. Grossi, F. Balestri, G. Beltrami, R. Bruni, M. Gobbi, I. Pierri, C. Musolino, C. Alati, F. Lussana, S.
Caberlon, F. Zallio, P. Mannucci, P. Bucciarelli, A. Zanella, F. Radaelli, A. Iurlo, G. Leonardi, M. Morucci, L.
Mastrullo, F. Gonnella, M.R. Villa, D. De Blasi, V. Martinelli, R. Ciancia, G. Gaidano, S. Franceschetti, G. Saglio, D.
Cilloni, F. Fabris, M.L. Randi, F. Porretto, M. Crugnola, F. Passamonti, E. Rumi, G. Davì, A. Dragani, E. Orciuolo,
G. O. Manenti, G. Garozzo, M. Salvucci, L. Gugliotta, A. Tieghi, C. Musto, L. Maurillo, M. De Muro, M. Cedrone, R.
Foà, M. G. Mazzucconi, R. Latagliata, C. Santoro, F. Saltarelli, L. Siracusano, F. Ardizzone, M. Iovine, N. Cascavilla,
R. P. Scalzulli, L. Melillo, M. Balboni, A. Candoni, F. Rodeghiero, M. Ruggeri, G. Castaman.
PATIENTS
42 %
10
THROMBOTIC RISK FACTORS
69 %
0
0-40
SPLENOMEGALY
25 %
PREGNANCIES
60
ASPIRIN
70%
True ET (WHO criteria)
60-70
70+
Diagnostic Criteria
PLT at Diagnosis
CYTOREDUCTION
Hydroxyurea
Anagrelide
Interferons 
Pipobroman
Busulfan
40-60
YEARS
63%
61%
12%
11%
4%
2%
<401
100
401-600
601-999
1000-1499
>=1500
80
60
%
RIT Panel
The Registro Italiano Trombocitemie (RIT) is a web- based registry
for the collection of clinical and biological data in ET patients.
The RIT is a project approved and supported by the GIMEMA
(Gruppo Italiano Malattie Ematologiche dell’Adulto)
Characteristic at diagnosis
40
27%
20
Normal KARYOTYPE
274 / 274
0
PVSG
Concluding Remarks
 The majority of the italian Haematological Centers are registering ET patients into the RIT.
The preliminary analysis of the 767 registered patients shows that in 92% of patients the diagnosis was done according to the PVSG criteria.
 In the ET patients, classified according to the WHO criteria, the rate of True ET ( 27%) was similar to that reported in other patient series
 The ongoing revision of the bone marrow biopsies will permit a reclassification according to the WHO criteria.
 Improvement of the diagnostic approach is expected and the harvest of biological material as been activated.
 A separate analysis is ongoing for specific series of patients treated with Anagrelide and Iterferons alpha.
WHO
OTHER